Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
103.148,60
-0,94%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pluri Inc (PLUR) Pluri Inc (PLUR) Notizie

PLUR

Pluri (PLUR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PLUR
DataOraFonteTitoloSimboloCompagnia
19/12/202414:00GlobeNewswire Inc.Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host DiseaseNASDAQ:PLURPluri Inc
09/12/202415:00GlobeNewswire Inc.Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025NASDAQ:PLURPluri Inc
27/11/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLURPluri Inc
25/11/202414:30GlobeNewswire Inc.Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat ConcernsNASDAQ:PLURPluri Inc
28/10/202412:00GlobeNewswire Inc.Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation AuthorityNASDAQ:PLURPluri Inc
30/09/202422:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PLURPluri Inc
20/09/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLURPluri Inc
18/09/202422:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PLURPluri Inc
18/07/202408:30GlobeNewswire Inc.Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product CandidatesNASDAQ:PLURPluri Inc
08/07/202413:00GlobeNewswire Inc.Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable SupplyNASDAQ:PLURPluri Inc
18/06/202412:30GlobeNewswire Inc.Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability ChallengesNASDAQ:PLURPluri Inc
06/06/202412:45GlobeNewswire Inc.U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome ContractNASDAQ:PLURPluri Inc
20/05/202413:00GlobeNewswire Inc.Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial ScaleNASDAQ:PLURPluri Inc
09/05/202422:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PLURPluri Inc
09/05/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLURPluri Inc
02/05/202413:00GlobeNewswire Inc.Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer TreatmentNASDAQ:PLURPluri Inc
08/04/202413:00GlobeNewswire Inc.Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New MethodNASDAQ:PLURPluri Inc
28/03/202412:15GlobeNewswire Inc.Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesNASDAQ:PLURPluri Inc
27/03/202412:00GlobeNewswire Inc.Pluri Inc. Announces 1-for-8 Reverse Share SplitNASDAQ:PLURPluri Inc
21/03/202412:00GlobeNewswire Inc.Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market ReportNASDAQ:PLURPluri Inc
19/03/202409:00GlobeNewswire Inc.Engage with Pluri's Talent: Exciting Conference Appearances AheadNASDAQ:PLURPluri Inc
14/03/202412:00GlobeNewswire Inc.Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug ManufacturingNASDAQ:PLURPluri Inc
11/03/202412:00GlobeNewswire Inc.Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell CultivationNASDAQ:PLURPluri Inc
06/03/202413:00GlobeNewswire Inc.Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory BoardNASDAQ:PLURPluri Inc
28/02/202413:00GlobeNewswire Inc.Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 GoalsNASDAQ:PLURPluri Inc
14/02/202423:43Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PLURPluri Inc
13/02/202422:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PLURPluri Inc
23/01/202408:00GlobeNewswire Inc.Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee CrisisNASDAQ:PLURPluri Inc
21/12/202313:00GlobeNewswire Inc.Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine AddictionNASDAQ:PLURPluri Inc
22/09/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PLURPluri Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PLUR

La tua Cronologia

LSE
0RGS
Archicom
NASDAQ
FCVVX
Bmo Balanced Etf Portfol...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network